GW Pharmaceuticals plc Reports 2013 Second Quarter Financial Results

barbara.lempert -Conference Call Today at 8:00 a.m. ET, 1:00 p.m. BST- London, UK, 3 June 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the ...

Synta Announces Positive Overall Survival Results from GALAXY-1 Phase 2b/3 Trial of Ganetespib

mia.burns Synta Announces Positive Overall Survival Results from GALAXY-1 Phase 2b/3 Trial of Ganetespib in Second-Line Non-Small Cell Lung Cancer   – Data presented at ASCO 2013 ...

AstraZeneca gets mixed results in Nexium patent fight with Hanmi

Eric Palmer AstraZeneca has gotten mixed results in a lawsuit agreement as it continues to try to hold generics at bay in the U.S. for its blockbuster stomach drug Nexium. It said today ...

Amgen trumpets T-Vec oncolytic virus results from PhIII melanoma study

John Carroll FierceBiotech News

iCo Therapeutics Announces First Quarter 2013 Financial Results

barbara.lempert VANCOUVER, May 29, 2013 /CNW/ – iCo Therapeutics (TSX-V: ICO), today reported financial results for the quarter ended March 31, 2013. Amounts, unless specified ...

iCo Therapeutics Announces Director Election Results from its Annual General Meeting of Shareholders

barbara.lempert VANCOUVER, May 24, 2013 /CNW/ – iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V: ICO) announced today that that all nominees listed ...

Omthera Pharmaceuticals Announces First Quarter 2013 Financial Results

barbara.lempert PRINCETON, N.J., May 28, 2013 /PRNewswire/ — Omthera Pharmaceuticals, Inc. (Nasdaq: OMTH), an emerging specialty pharmaceutical company, today announced its ...

Phytopharm Interim results for the six months ended 31 March 2013

barbara.lempert Phytopharm plc (PYM: London Stock Exchange) (“Phytopharm” or the “Company” or the “Group”) today announces its unaudited interim results for the six months ...

Novo Nordisk completes PhIII hemophilia trial with positive results

Emily Mullin In a Friday announcement, Novo Nordisk said it completed the first phase III trial of its drug N9-GP for hemophilia B patients. FierceBiotech News

Gilead keeps lead in hep C race after rivals post key trial results

Ryan McBride After delivering data from multiple rounds of trials on all-oral combos against hepatitis C, pharma runners appear to be making progress with new therapies that could ...
Page 7 of 7« First...34567
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS